Marinomed presented detailed data from the Phase III trial testing nasal spray Budesolv (budesonide aqueous solution) in allergic rhinitis ("AR") at the American College of Allergy, Asthma & Immunology ("ACAAI"). The company had already disclosed that the 75-patient trial had met both the primary endpoint non-inferiority to comparator Rhinocort Aqua (budesonide suspension) and the secondary endpoint faster onset of action. Today's update provided further details about the secondary endpoi
26 Nov 2019
flash note
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
flash note
- Published:
26 Nov 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
5
Marinomed presented detailed data from the Phase III trial testing nasal spray Budesolv (budesonide aqueous solution) in allergic rhinitis ("AR") at the American College of Allergy, Asthma & Immunology ("ACAAI"). The company had already disclosed that the 75-patient trial had met both the primary endpoint non-inferiority to comparator Rhinocort Aqua (budesonide suspension) and the secondary endpoint faster onset of action. Today's update provided further details about the secondary endpoi